This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Bionomics 대차 대조표 상태

재무 상태 기준 확인 6/6

Bionomics has a total shareholder equity of A$47.7M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$56.3M and A$8.6M respectively.

주요 정보

부채 비율

AU$0

부채

이자 보상 비율	n/a
현금	AU$30.70m
주식	AU$47.72m
총 부채	AU$8.59m
총 자산	AU$56.31m

최근 재무 상태 업데이트

Recent updates

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Jun 14

Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?

Feb 23

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Sep 14

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Nov 15

Did You Miss Bionomics' (ASX:BNO) 86% Share Price Gain?

Dec 30

재무 상태 분석

단기부채: BNO's short term assets (A$33.1M) exceed its short term liabilities (A$3.7M).

장기 부채: BNO's short term assets (A$33.1M) exceed its long term liabilities (A$4.9M).

부채 대 자본 내역 및 분석

부채 수준: BNO is debt free.

부채 감소: BNO has no debt compared to 5 years ago when its debt to equity ratio was 63.9%.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: BNO has sufficient cash runway for more than a year based on its current free cash flow.

예측 현금 활주로: BNO has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 9% each year.

This company listing is no longer active

Bionomics 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Recent updates

New minor risk - Financial data availability

Bionomics Completes Last Patient Last Visit in the Phase 2B Attune Study for Post-Traumatic Stress Disorder

New major risk - Market cap size

Bionomics Limited Appoints Tim Cunningham as Chief Financial Officer

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

First half 2023 earnings released: AU$0.012 loss per share (vs AU$0.013 loss in 1H 2022)

Is Bionomics (ASX:BNO) In A Good Position To Invest In Growth?

High number of new directors

Bionomics Limited Reports Results in PREVAIL Phase2 Study BNC210

High number of new and inexperienced directors

Bionomics Limited, Annual General Meeting, Nov 16, 2022

Is Bionomics (ASX:BNO) In A Good Position To Deliver On Growth Plans?

Full year 2022 earnings: EPS and revenues exceed analyst expectations

High number of new and inexperienced directors

High number of new and inexperienced directors

Bionomics Limited announced that it has received $2.794495 million in funding

Bionomics Initiates Phase 2 Prevail Study of Bnc210 for the Acute Treatment of Social Anxiety Disorder

High number of new directors

U.S. Food and Drug Administration Grants Bionomics Fast Track Designation to Bnc210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related Disorders

Companies Like Bionomics (ASX:BNO) Are In A Position To Invest In Growth

Bionomics Prepares BNC210 for Start of Phase 2 Acute Treatment of Social Anxiety Disorder Trial

Full year 2021 earnings released: AU$0.01 loss per share (vs AU$0.011 loss in FY 2020)

Bionomics Initiates Phase 2B ATTUNE Study of BNC210 in PTSD

Bionomics BNC210 Expansion into Social Anxiety Disorder

Legal Counsel & Company Secretary has left the company

Bionomics Limited has completed a Follow-on Equity Offering in the amount of AUD 15.991634 million.

New 90-day high: AU$0.39

Bionomics Limited Announces Positive BNC210 PK Results for Solid Dose Formulation

Bionomics Limited and EmpathBio Inc Joint Feasibility Assessment

Bionomics Limited announced that it expects to receive AUD 15.991634 million in funding

New 90-day high: AU$0.22

Bionomics Limited Completes Treatment Phase in the MODULATE Clinical Trial

Bionomics Limited Announces Publication of Positive BNC210 Phase 2a Data in Gad Patients

Bionomics Limited Initiates 7-Day Dosing Pharmacokinetic Study of BNC210

Did You Miss Bionomics' (ASX:BNO) 86% Share Price Gain?

Bionomics Limited Licenses Drug Candidate BNC101 to Carina Biotech

Bionomics Limited Announces Director Changes

Bionomics Limited announced that it has received AUD 5.43332 million in funding from Apeiron Investment Group Ltd. and other investors

Full year earnings released - AU$0.0082 loss per share

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기